Pamidronate “zebra lines”: A treatment timeline

Avgi Loizidou*, Savvas Andronikou, Christine P. Burren

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

3 Citations (Scopus)
258 Downloads (Pure)


Osteogenesis imperfecta is a hereditary bone dysplasia characterized by bone fragility, deformity, and short stature. Treatment focuses on preventing bone fractures and symptom relief. Pamidronate, a second-generation bisphosphonate drug that minimizes bone loss, is the chosen treatment in osteogenesis imperfecta. Radiologically, each cycle of pamidronate treatment is depicted as a line of sclerosed nondecalcified cartilage at the metaphysis, termed a pamidronate line. In this case report, we demonstrate that a treatment timeline can be visualized on plain radiographs as the number and spacing of pamidronate lines reflects the number and timing of treatment cycles. The educational value of this is to reassure physicians of the benign nature of “zebra lines,” to demonstrate that the pamidronate lines migrate and fade with bone growth, and alert physicians that the lack of expected pamidronate lines during treatment may reflect a change in the patient's condition that reduces the effectiveness of bisphosphonate infusions.

Original languageEnglish
Pages (from-to)850-853
Number of pages4
JournalRadiology Case Reports
Issue number4
Early online date9 Aug 2017
Publication statusPublished - 1 Dec 2017


  • Osteogenesis imperfecta
  • Bisphosphonate
  • Pamidronate lines


Dive into the research topics of 'Pamidronate “zebra lines”: A treatment timeline'. Together they form a unique fingerprint.

Cite this